Twentyeight-Seven Therapeutics develops small‑molecule approaches to modulate RNA by targeting RNA‑modulating proteins (RMPs) to control expression of oncogenes and other disease‑relevant proteins. Its lead program aims to restore levels of the tumor‑suppressive microRNA let‑7 by preventing binding of the LIN28 protein to let‑7 precursors. The company intends to use the new funding to accelerate current programs, build out its technology platform and expand into additional opportunities. Since the close of its initial $65M Series A in September 2018, Twentyeight‑Seven has moved into new facilities in Watertown, MA. The company is led by CEO Kazumi Shiosaki, Ph.D., and recently added Henrijette Richter of Sofinnova Partners to its board. The financing brings additional resources to advance its oncology‑focused pipeline and platform work. Twentyeight-Seven Therapeutics focuses on modulating non-coding RNA (ncRNA) biology by targeting RNA-modulating proteins (RMPs) with small molecules to treat cancer and other diseases. Its lead program aims to increase levels of the tumor suppressor microRNA Let-7 by inhibiting the RMP Lin28, a pathway implicated in cancer initiation, progression, and metastasis. The company’s approach deliberately avoids oligonucleotides and instead uses small molecules for broader cellular and tissue access. Core technology and targets originate from four founding scientists who have made seminal discoveries in ncRNA biology, including the Lin28/Let-7 pathway. 28-7 is developing first-in-class Lin28 inhibitors intended for serious cancer indications and plans to advance discovery and development with new funding. The company announced the hiring of Shomir Ghosh, Ph.D., as Chief Scientific Officer to support translational and preclinical work. Twentyeight-Seven is headquartered in Cambridge, Mass.

Total raised

$80M

Funding rounds

2

Latest round

Series A

Latest activity

May 2019